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Abstract
Background This study assessed the validity and reliability of the generic module of the recently developed Patient Experi-
ences and Satisfaction with Medications (PESaM) questionnaire in a sample of patients in the Netherlands.
Methods The generic module of the PESaM questionnaire consists of 18 items related to the domains effectiveness, side 
effects and ease of use of medications. It assesses patients’ experiences regarding the impact of the medication on daily life, 
health and satisfaction. In 2017, the PESaM questionnaire was sent out to idiopathic pulmonary fibrosis patients using pir-
fenidone or nintedanib, atypical haemolytic uraemic syndrome patients receiving eculizumab and patients using tacrolimus 
after kidney transplantation. Mean scores for each domain were calculated applying a scoring algorithm. Construct validity 
and reliability were assessed using recommended methods.
Results 188 participants completed the generic module, of whom 48% used pirfenidone, 36% nintedanib, 11% tacrolimus 
and 5% eculizumab. The generic module has good structural properties. Internal consistency values of the domains were 
satisfactory (i.e. Cronbach’s coefficient alpha above 0.7). Confirmatory factor analysis provided further evidence for con-
struct validity, with good convergent and discriminant validity. The PESaM questionnaire also showed different scores for 
patients using different medications, in line with expectations, and was therefore able to differentiate between patient groups. 
Test–retest reliability of the items and domains were rated as moderate to fair (i.e. intraclass coefficients ranged between 
0.18 and 0.76).
Conclusions The PESaM questionnaire is a unique patient-reported outcome measure evaluating patient experiences and 
satisfaction with medications. It has been developed in conjunction with patients, ensuring coverage of domains and issues 
relevant from the patient’s perspective. This study has shown promising validity of the generic module of the PESaM ques-
tionnaire. Further research is recommended to assess reliability in greater detail as well as the responsiveness of the measure.
Trial registration The study is registered in The Netherlands National Trial Register (Trial Code 5860).
Key Points 
The PESaM questionnaire is a unique patient-reported 
outcome measure developed in conjunction with patients 
to evaluate experiences and satisfaction with medica-
tions.
The generic module of the PESaM questionnaire has 
sound structural properties and construct validity.
Further research is recommended to assess the reliability 
and responsiveness of the measure.The members of the PESaM collaborating group have been listed 
in the Acknowledgements section.
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1 Introduction
It is widely acknowledged that the patient’s perspective 
regarding medical therapy should play a central role in 
deciding upon treatment strategies [1–11]. Patients who 
perceive their medication to be ineffective, suffer from side 
effects, or experience difficulties with the administration of 
a medication, are less likely to be satisfied and take their 
medication as prescribed [12]. This in turn can impact the 
effectiveness of the treatment [13], and may result in inef-
ficient use of healthcare resources [14]. Hence, systematic 
collection of patient experiences is useful in clinical prac-
tice, but may also play an important role in health technol-
ogy assessment (HTA) [1, 9, 15–18]. To date, the patient’s 
views and experiences are increasingly taken into account 
in the reimbursement decision-making process, mostly 
through active patient engagement; for example, through 
consultation rounds with patients or patient representa-
tives [15, 19, 20]. Quantitative data (e.g. questionnaires) 
of patient experiences, however, have great potential to 
strengthen the patient evidence that is taken into account 
[15, 19].
The Patient Experiences and Satisfaction with Medi-
cations (PESaM) questionnaire is a recently developed 
patient-reported outcome measure (PROM) for quan-
titative assessment of patient experiences and satisfac-
tion with (novel) drug therapies [21]. It was developed 
in response to the request of two patient organizations 
that wanted to better capture patients’ experience with 
expensive orphan drugs that had been granted conditional 
approval for reimbursement by the Dutch government. 
Conditional approval requires a national registry with 
data on physiological outcomes as well as evaluation of 
patient-relevant outcomes such as health-related quality 
of life (HRQoL) and patient experiences, as input for a 
re-evaluation after 4 years [22]. The orphan drugs were 
pirfenidone and nintedanib for the treatment of idiopathic 
pulmonary fibrosis (IPF) and eculizumab for atypical 
haemolytic uraemic syndrome (aHUS).
IPF is a chronic and progressive lung disease that is 
characterized by irreversible loss of lung function. For 
patients with IPF, prognosis is poor with an average sur-
vival of 3–5 years after diagnosis, and treatment options 
are limited [23]. Pirfenidone and nintedanib are both orally 
administered anti-fibrotic agents for treatment of mild to 
moderate IPF. Pirfenidone treatment entails taking three 
capsules (swallowed whole with water) three times daily 
with food [24]. Nintedanib treatment consists of tak-
ing one capsule twice daily with food, and with 12 h in 
between administrations [25].
Atypical HUS is an extremely rare and life-threatening 
disease characterized by suddenly abnormal breakdown 
of red blood cells, low platelet counts and acute renal fail-
ure due to the formation of blood clots in small vessels, 
particularly in the kidneys. In the Netherlands, it is esti-
mated that 15–20 people are diagnosed with aHUS each 
year, of whom five are children. The prognosis for people 
with aHUS is poor, with around 2–10% of people with the 
disease dying in the initial, acute phase [26, 27]. Eculi-
zumab is the first and only therapy approved for treatment 
of aHUS and is administered intravenously. Treatment 
with eculizumab consists of weekly infusions in the initial 
phase (up to 4 weeks) followed by eculizumab infusions 
every 14–21 days depending on the body weight of the 
patient, for potentially their entire life (according to the 
product summary of the European Medicines Agency). 
Following new Dutch guidelines, the interval between 
eculizumab administrations is gradually extended after 
3 months of treatment in patients who are stable and in 
remission [28].
The focus of the PESaM questionnaire is on a patient’s 
subjective experiences related to the impact of the effective-
ness and side effects of the medication on health and daily 
life, as well as the ease of use of the medication. It comprises 
two disease-specific modules evaluating drug treatment for 
IPF and aHUS, a generic module applicable to any medica-
tion and a module focused on patient expectations of the 
medication. The format and content of the PESaM question-
naire were based on a formal conceptual framework [29], 
a literature review and input from patients through focus 
groups and individual interviews [21]. Development and 
pre-testing of the questionnaire has been described exten-
sively elsewhere [21]. The aim of the study described in 
this paper was to assess the psychometric properties of the 
questionnaire, with a specific focus on the generic mod-
ule due to its wide applicability. The items of the generic 
module evaluate the positive (or negative) influence of a 
medication’s efficacy and side effects on physical health, 
emotional health and (ability to perform) social activities, 
and the influence of the medication’s mode of administration 
on daily life. In addition, satisfaction with each domain as 
well as overall satisfaction with the medication is assessed. 
The main focus of the psychometric evaluation was to test 
the construct validity of the measure, that is, the extent to 
which the scores on the generic module relate to other meas-
ures (or constructs) or vary between groups consistent with 
theoretically derived hypotheses [30]. Based on Strasser 
and colleagues’ model of satisfaction [29], we first tested 
the association between experiences and satisfaction. Next, 
due to the measure’s emphasis on the impact of the medica-
tion on HRQoL indicators, we tested associations between 
patient experiences and HRQoL, as measured by the EQ-5D, 
which also focuses on physical, emotional and social health 
[31]. Finally, it is important that the generic module is able 
to discriminate between patient groups that are expected 
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to differ in their experiences and satisfaction, for example 
because of different therapeutic effects of medications or 
time on medication. Results of the construct validity and 
reliability testing are presented and discussed in this paper.
2  Study Participants and Methods
2.1  Study Participants and Data Collection
The validity study was performed at 11 site hospitals across 
the Netherlands over a period of 1 year (July 2016–June 
2017) using a convenience sample of IPF patients using 
pirfenidone or nintedanib and aHUS patients receiving 
eculizumab treatment. In addition, a sample of patients was 
recruited that had not been involved in the development pro-
cess of the PESaM questionnaire. Patients using a once-a-
day oral formulation of tacrolimus (brand name Advagraf) 
after kidney transplantation were asked to complete the 
generic module only.
Inclusion criteria for the validity study were (1) being an 
adult (aged > 15 years) diagnosed with IPF, aHUS (first diag-
nosis or recurrence), or a history of kidney transplantation; 
(2) taking any of the following medications: pirfenidone or 
nintedanib, eculizumab, or tacrolimus, respectively; and (3) 
being able to read Dutch. There were no restrictions to the 
time on medication or treatment regimen. IPF patients were 
recruited in nine hospitals across the Netherlands. Atypical 
HUS patients received their treatment in the Radboud Uni-
versity Medical Center in Nijmegen, the national expertise 
centre for aHUS. Patients using tacrolimus were attending 
follow-up visits in the Maastricht University Medical Cen-
tre. The appropriate modules of the PESaM questionnaire 
were either handed out (on paper) to patients during outpa-
tient clinic follow-up visits or emailed via an online survey 
system.
Written informed consent was obtained prior to complet-
ing the questionnaire. The study protocol for the develop-
ment and testing of the measure was reviewed and approved 
by the Medical Ethics Committee of Erasmus Medical Cen-
tre (MEC-2015-265). The study is registered in The Nether-
lands National Trial Register (trial code 5860).
2.2  Measures
2.2.1  Generic Module of the PESaM Questionnaire
The generic module of the PESaM questionnaire consists of 
18 items related to the domains of effectiveness (4 items), 
side effects (4 items), ease of use (3 items) and satisfaction 
Table 1  Domains, items and response options of the generic module of the PESaM questionnaire
Domain Items Response options
Effectiveness Efficacy of medication No positive effectiveness to very positive effectiveness (5 
levels)
I don’t know
Positive influence on physical health (e.g. walking, cycling) No positive influence to very positive influence (5 levels)
I don’t knowPositive influence on feelings and emotions (e.g. fear, joy)
Positive influence on social activities (e.g. work, family, 
friends)
Satisfaction (or dissatisfaction) with effectiveness Thermometer − 5 (very dissatisfied) to + 5 (very satisfied)
Side effects Bothersomeness of side effects I did not experience side effects (continue to item 10)
Not bothersome to very bothersome (5 levels)
I don’t know
Negative influence on physical health (e.g. walking, cycling) No negative influence to very negative influence (5 levels)
I don’t knowNegative influence on feelings and emotions (e.g. fear, joy)
Negative influence on social activities (e.g. work, family, 
friends)
Satisfaction (or dissatisfaction) with side effects Thermometer − 5 (very dissatisfied) to + 5 (very satisfied)
Ease of use Inconvenience of administration mode Not inconvenient to very inconvenient (5 levels)
Inconvenience of time table (frequency)
Inconvenient to incorporate in everyday life
Satisfaction (or dissatisfaction) with ease of use Thermometer − 5 (very dissatisfied) to + 5 (very satisfied)
Overall satisfaction Overall (dis) satisfaction with medication Thermometer − 5 (very dissatisfied) to + 5 (very satisfied)
Importance of effectiveness Not important to very important (5 levels)
Importance of effectiveness
Importance of effectiveness
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(4 items) (Table 1). The final three items concern the per-
ceived importance of the effectiveness, side effects and ease 
of use of the medication. These items were included for vali-
dation purposes only. Items within the domains of effective-
ness and side effects relate to the impact of the medication 
on aspects of physical health, emotional health and daily life 
(social and work activities) [21]. These items all relate to 
subjective experiences of the respondent (e.g. to what extent 
did the side effects of the medication negatively influence 
your daily life?). The ease-of-use items focus on the admin-
istration mode and the (potential) interference of adminis-
tering the medications with daily life. Each domain has one 
item on satisfaction (e.g. how satisfied or dissatisfied were 
you with the ease of use of the medication?). In addition, 
there is an ‘overall satisfaction’ item asking the respondent 
to take all domains of the medication into account. A 5-point 
(Likert-type) scale with the following anchor levels was cho-
sen as the response format for items evaluating experiences: 
‘not at all’, ‘a little’, ‘reasonable’, ‘a lot’ and ‘very’. In the 
domains of effectiveness and side effects, a ‘don’t know’ 
response category was added. Items regarding satisfaction 
were scored using a (horizontal) thermometer, ranging from 
− 5 (very dissatisfied) to + 5 (very satisfied).
Mean scores for experiences in each domain of the 
generic module were calculated if at least two items of the 
domain were completed. Response categories were coded 
from 0 (‘not at all’) to 4 (‘very’) and the domain scores can 
therefore range between 0 and 4. The ‘don’t know’ response 
category was considered a missing value for the purpose 
of calculating mean scores. Higher scores in the domain 
of effectiveness represented higher positive experiences 
regarding the effectiveness of the medication, while in the 
domains of side effects and ease of use, higher scores rep-
resented higher burden from side effects and lower ease of 
use, respectively. To facilitate interpretation, original scores 
in the domains of side effects and ease of use were recoded 
so that higher scores represented low burden of side effects 
and ease of use (i.e. for all domains, higher scores represent 
positive experiences). The items related to satisfaction (i.e. 
items 5, 10, 14 and 15) were not recoded; the reported scores 
(ranging between − 5 and 5) were used.
2.2.2  Disease‑Specific Modules of the PESaM 
Questionnaire
IPF and aHUS patients completed the applicable disease-
specific module of the PESaM questionnaire in conjunction 
with the generic module. Similar to the generic module, the 
disease-specific modules focus on experienced effectiveness, 
side effects and ease of use of the medication, but do not 
include items regarding satisfaction. The items on effective-
ness assume a positive influence on health, the items on side 
effects a negative influence and the items on ease of use 
focus on the potential inconvenience of the specific mode of 
administration and whether patients have skipped medica-
tion. The difference between these and the generic module is 
that the disease-specific modules evaluate the effectiveness 
of the medication on specific disease symptoms. For exam-
ple, the module for aHUS asks about the influence of eculi-
zumab on energy levels, the ability to participate in society 
and fear of infection (meningitis), and provides a checklist 
of potentially experienced side effects. The module for IPF 
focuses on its perceived ability to slow down disease pro-
gression, reduce coughing, feeling tired, out of breath and 
whether respondents experienced side effects such as pho-
tosensitivity, nausea and diarrhoea. Details on the contents 
and response levels (e.g. which side effects are included) 
can be found in our earlier paper [21]. Response levels and 
the scoring of domain scores for effectiveness and ease of 
use are similar to the generic module and range between 
0 and 4. For each experienced side effect, respondents are 
asked to rate how bothered they are by that side effect and a 
sum score for this domain is calculated by multiplying the 
number of side effects with the respondent’s average rating 
of bothersomeness. Thus, a higher score represents a higher 
level of bothersomeness experienced due to one or more 
side effects.
2.2.3  EQ‑5D
Participants completed the EQ-5D (3-level version) to meas-
ure HRQoL [31]. The EQ-5D consists of two components: 
a descriptive system of health and a visual analogue rating 
scale (VAS). The descriptive system consists of five items 
(mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression), each with three response levels (no 
problems, some problems and severe problems). Reported 
health states on the descriptive system are converted to an 
EQ-5D index score where 1 represents full health and 0 
represents death [32]. The EQ-VAS records the respond-
ent’s self-rated health on a 0–100 scale, with the endpoints 
respectively labelled ‘worst imaginable health state’ and 
‘best imaginable health state’.
2.2.4  Demographic and Clinical Data
Date of birth, gender, date of diagnosis, medication and time 
on medication were collected from electronic medical files. 
For IPF patients, forced vital capacity (FVC) at diagnosis 
and around completion date of the questionnaire were col-
lected, expressed in percentage and litres.
2.3  Data Analysis
Due to a limited number of repeated measurements, a 
cross-sectional dataset was used for testing psychometric 
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properties of the generic module. In case participants had 
completed the questionnaires at multiple time-points during 
the study, only their first completed questionnaire was used 
for this analysis.
2.3.1  Structural Properties
A stacked bar chart graphically presents the distribution 
of scores, percentage of missing values, and ‘don’t know’ 
responses. Floor and ceiling effects were considered present 
when at least 15% of respondents scored the lowest or high-
est possible score, respectively [33].
2.3.2  Internal Consistency
Internal consistency as a measure of the extent to which the 
items in the domains of effectiveness, side effects and ease 
of use are correlated (homogeneous), thus measuring the 
same concept, was assessed by calculating the Cronbach’s 
alpha for each domain separately. A low Cronbach’s alpha 
indicates a lack of correlation between the items, which 
makes summarizing the items unjustified. The internal con-
sistency was considered good when Cronbach’s alpha was 
between 0.70 and 0.95 [30].
2.3.3  Construct Validity
Confirmatory factor analysis (CFA) with robust maximum 
likelihood estimation was used to test the factor structure 
of the generic module. We hypothesized that items 1–4 
measure the latent construct ‘experienced effectiveness’, 
items 6–9 ‘bothersomeness of side effects’, and items 
11–13 represent ‘ease of use’. First, goodness-of-fit indi-
ces were used to evaluate the adequacy of the model’s fit 
to the data, including the Chi-square value, comparative fit 
index (CFI), Tucker–Lewis index (TLI), root mean square 
error of approximation (RMSEA) accompanied by its 90% 
confidence interval (CI) and standardized root mean square 
residual (SRMR). CFI and TLI values exceeding 0.95, and 
SRMR and RMSEA values close to (or less than) 0.08 and 
0.06, respectively, represented a good fit [34]. Second, con-
vergent validity was examined by assessing the size and 
significance of the factor loadings (using the standardized 
regression coefficients) and the average variance extracted 
(AVE) for each factor, which should exceed 0.50 [35]. 
Finally, discriminant validity (i.e. whether each one of the 
domains has enough discriminant validity from the other 
domains) was evaluated and considered good when the cor-
relation coefficients between the three domains were < 0.8.
Construct validity was further assessed by investigat-
ing whether scores on the domains (i.e. constructs) of the 
PESaM generic module (e.g. experiences and satisfaction) 
relate to other constructs in a manner that is consistent with 
a priori hypotheses [30, 36]. The following hypotheses were 
tested:
1. It was a priori expected that patient experiences have 
a medium to high correlation with satisfaction; more 
positive experiences (e.g. low burden of side effects) are 
associated with higher levels of satisfaction [4, 29, 37].
2. It was expected that the effectiveness of the medication 
was considered the most important domain of medica-
tion use to patients and therefore that ‘satisfaction with 
effectiveness’ and ‘experiences with effectiveness’, 
respectively, have the largest independent contribution 
to overall satisfaction, relative to the contributions of the 
other domains (i.e. side effects and ease of use).
3. Positive patient experiences in the PESaM refer to an 
experienced positive impact on physical, emotional and 
social health, respectively. It was therefore expected that 
patient experience scores for the domains effectiveness 
and side effects of the medication were moderately cor-
related with HRQoL [4, 38, 39].
4. Patient experiences of IPF and aHUS patients regarding 
effectiveness, side effects, and ease of use, as reported in 
their respective disease-specific modules, were expected 
to have a strong (positive) correlation with the corre-
sponding experiences as reported in the generic module.
The strength and direction of the associations were 
measured using the Pearson product-moment correlation or 
Spearman’s rank-order correlation coefficient, depending on 
the distribution of the mean scores or measurement scale 
(hypotheses 1, 3 and 4). A correlation coefficient between 
0.90 and 1.00 would indicate a very high positive correla-
tion, 0.70–0.90 a high (positive) correlation, 0.50–0.70 a 
moderate (positive) correlation, 0.30–0.50 a low (positive) 
correlation, and 0–0.30 a negligible correlation [40].
Multiple regression analyses (enter method) were con-
ducted to examine the relationship between overall satis-
faction (item 15) and several proposed predictors (hypoth-
esis 2). Unstandardized regression coefficients (B) and 
explained variance (adjusted  R2) were estimated for two 
multiple regression models: (i) satisfaction with effective-
ness (item 5), satisfaction with side effects (item 10), and 
satisfaction with ease of use (item 4) as predictors of over-
all satisfaction; and (ii) experiences with effectiveness 
(domain score), experiences with side effects (domain 
score), and experiences with ease of use (domain score) 
as predictors of overall satisfaction. Mean scores on the 
patients’ rating of importance of each domain (items 16, 
17 and 18 of the generic module) were compared using 
repeated measures ANOVA and post hoc testing (Bonfer-
roni). Subsequently, the ranking of the importance of the 
domains (in case of significant differences between mean 
scores) were compared with the results of the regression 
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models (i.e. the size and significance of the independent 
contribution of a domain to overall satisfaction). It was 
hypothesized that a direct measurement of the importance 
of domains (items 16–18) would produce a ranking that 
is similar to results of the regression analyses (where the 
domain with the largest regression coefficient is consid-
ered to be the most important domain to the patient).
Known-groups validity (i.e. whether an instrument 
shows different scores for groups that in theory should 
have different scores) was tested by comparing mean 
scores of the different medications.
We expected varying scores between the drugs for dif-
ferent diseases due to varying therapeutic effects, side 
effects and modes of administration. More specifically, 
we tested the following hypotheses:
1. It was expected that patient experiences regarding effec-
tiveness were more positive for eculizumab and tacroli-
mus compared with pirfenidone or nintedanib, since 
the latter therapies aim to reduce disease progression, 
which may be difficult to experience by patients over 
short periods (i.e. ‘the past 4 weeks’).
2. It was expected that eculizumab users report less posi-
tive experiences with ease of use, due to the intravenous 
administration requiring inpatient hospital visits.
3. No major differences in ease of use were expected 
between pirfenidone, nintedanib and tacrolimus, all 
requiring oral administration.
4. A final hypothesis is that long-term users of a medica-
tion (i.e. > 2 months on medication) had more positive 
experiences and were more satisfied with a medication 
compared with new users (i.e. ≤ 2 months) [37].
Analysis of variance (ANOVA) with post hoc (Tukey) 
testing was used for comparing scores between medica-
tions. The independent sample t test was used when two 
groups (i.e. new users vs long-term users) were compared. 
A p value of 0.05 was used as the cut-off for significance.
2.3.4  Reliability
A subsample of patients in stable health, as determined by 
their healthcare provider, were asked to complete the generic 
module a second time, 2 weeks after their initial completion 
(test–retest). The Intraclass Correlation Coefficient (ICC) 
was used to test the reliability of the questionnaires between 
the two measurements [41]. ICC estimates and their 95% 
confident intervals were calculated based on absolute agree-
ment and a 2-way mixed-effects model. Following recom-
mendations by Terwee et al., the reliability is positively rated 
when the ICC is at least 0.70 [30].
Statistical analyses were performed in SPSS statistical 
package version 23 (IBM SPSS, IBM) and R version 3.5.1 
using the lavaan package [42].
3  Results
A total of 188 patients (48% pirfenidone, 36% nintedanib, 
11% tacrolimus, 5% eculizumab) completed the generic 
module of the PESaM questionnaire. Of these patients, 116 
also completed (all items of) the EQ-5D, 159 completed the 
disease-specific module (93% IPF and 7% aHUS), and 39 
completed the generic module twice for test–retest meas-
urement purposes. The median time on medication was 
9 months (range 1–230 months). Characteristics of the study 
sample are presented in Table 2.
3.1  Structural Properties
The distribution of response levels was satisfactory for most 
items of the generic module (see Fig. 1). All items, except 
items 11 and 13, showed responses across the full range 
of response options. There were < 1% missing responses on 
the items in the domains of effectiveness and ease of use. 
Within the domain of side effects, there were between 3 
and 10% missing responses on individual items. Highest use 
(31%) of the ‘don’t know’ category was for item 1 of the 
questionnaire: “to what extent did you experience a positive 
effect of the medication?” Responses on the items related 
Table 2  Patient characteristics of the validity study
*Time since kidney transplant
Patient characteristics Pirfenidone
(n = 91)
Nintedanib (n = 67) Eculizumab (n = 10) Tacrolimus (n = 20) All (n = 188)
Mean age in years (min–max) 72 (52–86) 72 (58–85) 42 (26–72) 63 (37–76) 69 (26–86)
Sex, male (%) 75 (82) 54 (81) 4 (40) 9 (45) 142 (76)
Time since diagnosis in months, median (min–
max)
15 (1–122) 12 (1–78) 74 (1–153) 87 (12–230)* 16 (1–230)
Time on medication in months, median (min–
max)
12 (1–57) 5 (0–48) 7 (0–15) 87 (12–230) 9 (0–230)
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to satisfaction generally covered the full range of response 
categories (− 5 to  5) and there were few missing responses 
(< 1%). The mean scores were 2.2 (SD 2.4), 1.9 (SD 2.8), 
3.3 (SD 1.9) and 2.6 (SD 2.3) for the satisfaction items in 
the domains of effectiveness (item 5), side effects (item 10), 
ease of use (item 14), and overall satisfaction (item 15), 
respectively.
Floor and ceiling effects were considered present in an 
item when at least 15% of respondents scored the lowest 
or highest possible score, respectively. A floor effect was 
identified in items 2, 3 and 4 of the effectiveness domain; for 
each item, approximately 20% of respondents did not experi-
ence any positive effect of the medication. In the side effects 
domain, between 40 and 50% of the respondents reported 
the highest possible score on each item, and for items in the 
domain for ease of use, the ceiling effect was significant with 
approximately 60% and 81% of respondents reporting the 
highest level (i.e. no problems with ease of use).
3.2  Internal Consistency
The internal reliability of the domains of effectiveness, side 
effects, and ease of use was examined. The Cronbach’s alpha 
values were 0.92, 0.93 and 0.80, respectively, and fell within 
the recommended range of 0.70–0.95, providing evidence 
for internally consistent (homogeneous) scales [30].
3.3  Construct Validity
Figure 2 is a diagrammatic representation of the CFA of the 
generic module of the PESaM questionnaire. Listwise dele-
tion of cases missing any variable in the dataset resulted in 
86 used observations (out of a total of 188). The Chi-square 
statistic was not significant (Chi-square value 37.94, df = 41, 
p = 0.607), representing an acceptable model. The RMSEA 
was zero (90% CI 0.000–0.065) and both the CFI value of 
1.000 and TFI value of 1.006 exceeded 0.90, suggesting a 
model with satisfactory fit. Convergent validity was consid-
ered good, with moderate to large sizes of all factor loadings 
(all significant with p < 0.001) (Fig. 2). In addition, the AVE 
Fig. 1  Stacked bar chart of 
response distribution of the 
experience items in the generic 
module of the PESaM question-
naire (n = 188). Responses 
presented are the recoded scores 
so that high scores indicate 
positive experiences (e.g. a 
score of 4 represents ‘very 
positive influence’, ‘no negative 
influence’ and ‘very convenient’ 
for the domains effectiveness, 
side effects and ease of use, 
respectively)
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Fig. 2  Results of the confirmatory factor analysis
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for effectiveness, side effects and ease of use were 0.753, 
0.595 and 0.624, respectively, and were considered satis-
factory (i.e. values > 0.50). Finally, correlation coefficients 
between the three hypothesized factors (i.e. effectiveness, 
side effects and ease of use) ranged from −0.075 (p = 0.454) 
to 0.371 (p = 0.003) and were well below the 0.80 threshold 
value supporting discriminant validity between the domains.
In line with the first hypothesis, there was a significant 
moderately positive association between patient experiences 
and satisfaction for the domains of effectiveness and side 
effects (Spearman’s Rho 0.699 and 0.625, respectively). 
However, there was a low association between experiences 
and satisfaction for the ease of use domain (Spearman’s Rho 
0.475). Second, we expected there to be a low to moderate 
correlation between experiences with effectiveness and side 
effects (thus their impact on health) and HRQoL. Contrary 
to this expectation, positive experiences with effectiveness 
were not associated with a better HRQoL as represented by 
a higher EQ-5D index score (Pearson’s r = 0.175, p = 0.100). 
Patient experiences with effectiveness did have a low cor-
relation with HRQoL as reported on the VAS (Pearson’s 
r = 0.397, p < 0.001). Positive experiences with side effects 
(i.e. a low burden and impact on health) were found to have 
a low, but significant, correlation with the EQ-5D index 
and the VAS (Pearson’s r = 0.386, p < 0.001 and Pearson’s 
r = 0.271, p = 0.007, respectively). Finally, strong associa-
tions were found between experiences with effectiveness, 
side effects and ease of use as reported on the generic mod-
ule of the PESaM questionnaire and corresponding domains 
on the disease-specific modules (data not shown). For exam-
ple, the score of IPF patients on the domain experiences with 
effectiveness of the generic module, represented by general 
items such as experienced impact on physical health and 
impact on daily life, was highly correlated with the score 
for patient ‘experiences with effectiveness’ as measured by 
the disease-specific module that includes items on disease 
progression, cough and fatigue to evaluate effectiveness 
(Spearman’s Rho 0.872, p < 0.001). Correlation coefficients 
for side effects and ease of use between the generic and dis-
ease-specific modules were 0.617 and 0.782 (all p < 0.001), 
respectively.
Regression analyses identified the item ‘satisfaction 
with effectiveness’ as the strongest predictor of ‘overall 
satisfaction’ (B = 0.63, p < 0.001), relative to the contribu-
tion of ‘satisfaction with side effects’ (B = 0.20, p < 0.001) 
and ‘satisfaction with ease of use’ (B = 0.16, p = 0.049), 
with the model explaining 70% of the variance (adjusted 
R2 = 0.70). In the second regression model that examined 
the impact of the domains of patient experiences on overall 
satisfaction, ‘experiences with effectiveness’ was identified 
as the strongest predictor of overall satisfaction (B = 1.25, 
p < 0.001), relative to the contribution of ‘experiences with 
side effects’ (B = 0.81, p < 0.001) and ‘experiences with ease 
of use’ (B = 0.29, p = 0.263). The performance of this model 
was reasonable, explaining 50% of the variance (adjusted 
R2 = 0.50).
Results of the regression models were reasonably in line 
with the scores reported on items 16, 17 and 18 of the generic 
module where the effectiveness of medication was found to 
be of highest importance to respondents (mean score of 3.6 
with SD 0.8), followed by ease of use with a mean score of 
2.5 (SD 1.3) and side effects with a mean score of 2.4 (SD 
1.3). Repeated measures ANOVA showed that the difference 
between the mean importance scores of the domains were 
statistically significant (F(2, 362) = 92.498, p < 0.001). Post-
hoc tests using the Bonferroni correction revealed that there 
was a significant difference between item 16 (effectiveness) 
and item 17 (side effects) (p < 0.001) and item 16 and item 
18 (ease of use) (p < 0.001). However, the mean importance 
scores for items 17 and 18 were not significantly different 
(p = 0.268). Thus, while ease of use received a score as high 
as side effects when patients were asked to rate the impor-
tance of the medication characteristic directly, regression 
models showed that, relative to the domains of effectiveness 
and side effects, ease of use experiences contributed the least 
to overall satisfaction with the medication.
3.3.1  Known‑Groups Validity
We observed varying scores for different patient groups 
that completed the PESaM questionnaire. As hypothesized, 
patients using eculizumab or tacrolimus reported more posi-
tive experiences regarding effectiveness of the medication 
than patients using pirfenidone or nintedanib (Table 3). The 
higher score for tacrolimus (mean 2.5) compared with pir-
fenidone (mean 1.1) and nintedanib (mean 1.5) was statis-
tically significant (p = 0.001 and p = 0.008, respectively). 
However, the score for eculizumab (mean 2.2) was not sig-
nificantly different to the mean scores for pirfenidone and 
nintedanib, with p = 0.132 and p = 0.302, respectively. This 
may be explained by the small sample of eculizumab users.
Secondly, as hypothesized, patients using eculizumab 
generally reported less positive experiences and lower sat-
isfaction scores in the domain ‘ease of use’ compared with 
the oral therapies. Nevertheless, except for the difference in 
satisfaction between eculizumab (mean 2.0) and tacrolimus 
(mean 4.3) (p = 0.022), the differences between the medica-
tions lack statistical significance (p = 0.083 and p = 0.080 
for the differences with pirfenidone and nintedanib, respec-
tively). Third, as expected, patient experiences in the domain 
‘ease of use’ for the three oral medications were indeed very 
similar, with the exception that the satisfaction score for ease 
of use was significantly higher for tacrolimus (mean 4.3, 
SD 1.1) compared with pirfenidone and nintedanib (mean 
3.3, SD 1.7, p = 0.016 and mean 3.3, SD 2.0, p = 0.022, 
respectively).
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Finally, higher mean satisfaction scores for long-term 
users compared with new users were observed across all 
domains, although the difference in satisfaction of side 
effects did not reach statistical significance (Table 4). Inter-
estingly, although satisfaction levels were generally higher, 
the experienced ease of use of the medication did not differ 
between new and long-term users.
The patient groups differed regarding type of medica-
tion (and thus administration mode, therapeutic effect and 
side effects), but also in time on medication, severity of dis-
ease and probably other patient characteristics that were not 
measured in this study. Score differences should therefore 
only be interpreted for validity testing and not be used for a 
direct comparison between medications.
3.4  Reliability
A test–retest measurement was conducted in a subgroup 
of 39 patients, of whom 18 used pirfenidone, six used 
nintedanib and 15 used tacrolimus. The mean age of the 
patients was 68 years old (range 37–86) and 69% were 
male. The average time on treatment was 35 months (range 
1 month–27 years). The mean time on treatment for tacroli-
mus patients was 6 years (range 1–24 years), while for IPF 
it was 12 months (range 1–57 months). The ICCs for single 
Table 3  Mean scores (SD) for pirfenidone, nintedanib, tacrolimus and eculizumab
The significant p values are in bold (p ≤ 0.05)
a The number of respondents vary between 76 and 91 because a domain score could not always be calculated (e.g. when > 2 responses were miss-
ing or ‘don’t know’)
b The number of respondents vary between 49 and 58
c The number of respondents vary between 14 and 20
d The number of respondents vary between 7 and 10
e Domain scores range between 0 and 4, with higher scores representing more positive experiences
f Satisfaction scores range between − 5 (very dissatisfied) and 5 (very satisfied)
Domains Pirfenidonea, n = 76 Nintedanibb, n = 49 Tacrolimusc, n = 14 Eculizumabd, n = 7 ANOVA
Mean (SD) Mean (SD) Mean (SD) Mean (SD) F p value
Experiences with  effectivenesse 1.3 (1.1) 1.5 (1.0) 2.5 (0.9) 2.2 (1.1) F (3.150) = 6.3 < 0.001
Experiences with side  effectse 3.0 (1.0) 3.3 (0.9) 3.8 (0.4) 2.4 (1.4) F (3.157) = 6.1 0.001
Experiences with ease of  usee 3.6 (0.5) 3.6 (0.6) 3.8 (0.4) 3.2 (0.7) F (3.183) = 2.8 0.040
Satisfaction with  effectivenessf 1.9 (2.5) 1.9 (2.2) 3.7 (1.7) 3.7 (1.6) F (3.182) = 5.4 0.001
Satisfaction with side  effectsf 1.6 (2.9) 2.0 (2.8) 3.2 (1.9) 1.8 (3.0) F (3.180) = 1.7 0.165
Satisfaction with ease of  usef 3.3 (1.7) 3.3 (2.1) 4.3 (1.1) 2.0 (2.9) F (3.184) = 3.4 0.019
Overall  satisfactionf 2.4 (2.4) 2.4 (2.3) 4.1 (1.5) 3.5 (1.9) F (3.182) = 3.8 0.012
Table 4  Mean scores (SD) for 
new (<  2 months) and long-
term (≥ 2 months) users
The significant p values are in bold (p ≤ 0.05)
a The number of respondents vary because a domain score could not always be calculated (e.g. when > 2 
responses were missing or ‘don’t know’)
b Domain scores range between 0 and 4, with higher scores representing more positive experiences
c Satisfaction scores range between − 5 (very dissatisfied) and 5 (very satisfied)
Domains New  usersa, N = 26–33 Long-term 
 usersa, N = 128–
153
Independent t test
Mean (SD) Mean (SD) t p value
Experiences with  effectivenessb 1.0 (0.8) 1.6 (1.1) t (152) = − 2.7 0.007
Experiences with side  effectsb 3.2 (1.2) 3.2 (0.9) t (159) = 0.1 0.942
Experiences with ease of  useb 3.6 (0.5) 3.6 (0.5) t (185) = − 0.5 0.630
Satisfaction with  effectivenessc 1.0 (2.5) 2.4 (2.3) t (184) = − 3.1 0.003
Satisfaction with side  effectsc 1.3 (2.9) 2.0 (2.8) t (182) = − 1.2 0.217
Satisfaction with ease of  usec 2.8 (2.2) 3.4 (1.8) t (186) = − 1.9 0.061
Overall  satisfactionc 1.9 (2.6) 2.8 (2.2) t (184) = − 2.1 0.042
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items were generally classified as moderate and the ICCs 
for domain scores as fair. Items regarding ease of use and 
the subsequent domain score show very low ICCs suggest-
ing poor reliability (Table 5). Visual inspection of the data 
showed that individual scores were almost identical for the 
two measurements, but little variation and a couple of outli-
ers were likely to cause low and unreliable values for the 
domain ‘ease of use’ [41].
4  Discussion
It is increasingly acknowledged that the patient’s perspec-
tive is of great importance when assessing the value of 
healthcare technologies. The generic module of the PESaM 
questionnaire was specifically developed to evaluate the per-
ceived effectiveness, side effects and ease of use of medi-
cations, and how these experiences impact on a patient’s 
health and daily life. Here we report for the first time on 
the psychometric properties of the PESaM questionnaire. 
This study showed that the generic module of the PESaM 
questionnaire is easy to complete and has good construct 
validity. The reliability of the measure is rated as moderate 
to fair and requires further investigation.
Structural properties of the generic module were satis-
factory, with good response distribution and few missing 
items. Of note was the relatively high proportion (19–31%) 
of respondents that used the ‘don’t know’ response category 
in the effectiveness domain. The items may have been too 
general or difficult for respondents who have a disease such 
as IPF (84% of the sample). Inherent to the nature of the 
disease, the aim of treatment is to slow down lung function 
decline, which is often not subjectively experienced by the 
patient. Moreover, interviews held with IPF patients revealed 
that patients may find it difficult to discern the effects of pir-
fenidone or nintedanib from the effects of other medications 
and treatments they were receiving (e.g. physical rehabilita-
tion or medications to treat side effects and co-morbidities), 
possibly leading them to a ‘don’t know’ response [21]. Since 
the PESaM questionnaire explicitly links the evaluated 
patient outcomes (experiences and satisfaction) to the inter-
vention (medication), the ‘don’t know’ response category 
was added to ensure that respondents do not feel forced into 
a response category they cannot relate to. Another notable 
finding was the floor and ceiling effects identified in the 
study. Floor and ceiling effects may be considered a threat 
to validity due to the loss of ability to detect improvements 
or deteriorations. Ceiling effects were most prominent in 
the domains of ease of use and side effects. However, in this 
case, ceiling effects may be due to the specific sample used. 
The majority of the study sample used easy-to-administer 
tablets, two to three times a day, and had been using the 
Table 5  Intraclass correlations 
(ICC) for each item at T1 and 
T2 (n = 39)
a ICC for absolute agreement
Item T1, mean (SD) T2, mean (SD) ICCa, (95% CI)
Effectiveness
 Efficacy of medication 2.7 (1.3) 2.5 (1.3) 0.57 (0.22–0.79)
 Physical health 1.9 (1.3) 2.0 (1.1) 0.71 (0.47–0.86)
 Feelings and emotions 1.7 (1.2) 1.6 (1.2) 0.59 (0.31–0.78)
 Social activities 1.9 (1.2) 2.1 (1.1) 0.71 (0.47–0.86)
Domain score effectiveness 2.0 (1.7) 1.9 (1.1) 0.76 (0.57–0.88)
Satisfaction (or dissatisfaction) 2.5 (2.4) 2.7 (2.0) 0.66 (0.43–0.81)
Side effects
 Bothersomeness side effects 3.5 (0.8) 3.2 (1.1) 0.61 (0.34–0.78)
 Physical health 3.6 (0.8) 3.6 (0.7) 0.52 (0.21–0.84)
 Feelings and emotions 3.8 (0.6) 3.6 (0.7) 0.71 (0.49–0.84)
 Social activities 3.7 (0.7) 3.7 (0.6) 0.50 (0.18–0.84)
Domain score side effects 3.6 (0.7) 3.5 (0.7) 0.75 (0.56–0.87)
 Satisfaction (or dissatisfaction) 3.6 (0.7) 3.5 (0.7) 0.72 (0.53–0.84)
Ease of use
 Administration mode 3.9 (0.3) 3.9 (0.4) 0.39 (0.09–0.62)
 Time table (frequency) 3.7 (0.7) 3.7 (0.5) 0.42 (0.12–0.65)
 Incorporate in everyday life 3.7 (0.7) 3.7 (0.5) 0.18 (-0.15–0.47)
Domain score ease of use 3.8 (0.4) 3.8 (0.4) 0.48 (0.19–0.69)
 Satisfaction (or dissatisfaction) 4.0 (1.3) 3.8 (1.7) 0.47 (0.18–0.68)
Overall satisfaction
 Overall (dis) satisfaction 3.3 (2.0) 3.3 (1.8) 0.76 (0.59–0.87)
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medication for some time. It is likely that the sample had 
become used to incorporating the medication into daily life, 
reporting little to no problems with ease of use. Furthermore, 
a large proportion of the respondents were not experiencing 
side effects at the time of measurement (on average 9 months 
on medication), which resulted in the maximum (positive) 
score for this domain. The ceiling effect present in the 
domain ‘ease of use’ may have also impacted the test–retest 
measurement, since the magnitude of an ICC decreases the 
more similar participants score to each other as a group [43]. 
Future studies, including medications administered via other 
routes, should confirm this rationale.
Confirmatory factor analysis provided evidence of the 
construct validity of the measure. Good model fit suggests 
that the data adequately represent the underlying theory of 
the measure. Furthermore, low correlations between the 
domains and high factor loadings support discriminant and 
convergent validity of the measure. Since the internal con-
sistency of the domains was also rated as very good, the 
domains appear to be sufficiently homogeneous for their 
items to be pooled.
Most hypotheses regarding associations with similar or 
dissimilar constructs were met. Following Strasser’s concep-
tual model of patient satisfaction, experiences and satisfac-
tion are related but quite distinct concepts, with multiple 
factors influencing the strength of their association, such 
as a patient’s expectations, beliefs and value system [29]. 
For example, a respondent may report a negative impact of 
side effects on daily life, but may not be dissatisfied because 
these side effects were expected. This study confirmed a 
positive association between experiences and satisfaction 
that was only of moderate strength. Furthermore, findings 
showed that while experiences were sometimes not very dif-
ferent between groups, for example between new and long-
term users of medications, satisfaction scores were signifi-
cantly higher among long-term users. A major strength of 
the PESaM questionnaire is thus that it specifically distin-
guishes between the patient’s experiences and the patient’s 
satisfaction. Other generic measures of patient experi-
ences with medication, such as the Treatment Satisfaction 
Questionnaire for Medication (TSQM) [37] and Treatment 
Satisfaction with Medicines Questionnaire (SATMED-Q) 
[44], generally have a stronger focus on satisfaction, with 
no means to separate the two concepts.
Contrary to expectations, positive experiences with 
effectiveness were not associated with a better HRQoL 
as measured by the EQ-5D, and the association between 
patient experiences with side effects and HRQoL was rather 
weak. It may be that our hypothesis was incorrect and that 
actually patients with worse HRQoL have more opportu-
nity to benefit from the medications and thus more posi-
tive experiences resulting in a negative relation (or at least 
a blurred relationship due to patients with different health 
states). Longitudinal data are better suited to explore the 
relationship between HRQoL and experiences. This find-
ing does emphasize that HRQoL measures alone, as a way 
to incorporate the patient’s perspective, are insufficient to 
fully grasp the patient’s experience of a drug therapy. We 
observed the correlation between the generic and disease-
specific measure to be very strong, however, which encour-
ages the use of the shorter generic module in both research 
and clinical settings. The generic module can promote more 
coherent outcome reporting across studies investigating the 
effectiveness of medications that aim to include an evalua-
tion of patient experiences.
Finally, the PESaM scores generally adhered to expected 
patterns across the therapeutic effectiveness of medications 
and their mode of administration and were able to distin-
guish between patients who just started on their medica-
tion and long-term users. These findings further support the 
overall validity of the tool.
A number of other limitations related to the study design 
need to be considered. First, the generic module was tested 
in the same disease population that was involved in the 
development of the measure. While a small sample of 
patients with a different disease were involved (i.e. patients 
using tacrolimus), the majority of the study population were 
IPF and aHUS patients. Extrapolation of the results to other 
medications or diseases must therefore be performed with 
due caution. Furthermore, the lack in variety of medications 
impacted on the validity tests. It was difficult to assess, for 
example, whether ceiling effects identified in the study were 
due to the metric properties of the questionnaire or due to the 
nature of the disease and medication of the majority of the 
study population (i.e. IPF). While we attempted to include 
participants using other medications, only small samples 
for eculizumab and tacrolimus were obtained. Due to the 
extreme rarity of aHUS and hence the use of eculizumab, 
and the small sample of tacrolimus patients, separate validity 
tests (e.g. multiple comparison testing as part of ANOVA) 
for these groups were hindered by a lack of power. In this 
study, however, the development of the PESaM question-
naire was a specific response to patient organizations and 
clinicians interested in collecting patient evidence of novel 
drug therapies in this population of patients with rare dis-
eases. Reliability testing was also affected by the relatively 
high proportion of ‘don’t know’ responses, which were to be 
considered as a missing value for calculation of ICCs (which 
is not suitable for categorical variables). This reduced the 
sample size for items with this response category available 
(i.e. items in the domains of effectiveness and side effects) 
resulting in a sample that may be considered too small for 
proper reliability analysis. Further investigation of the reli-
ability of the measure is recommended. Unfortunately, due 
to logistic reasons, insufficient data were available to assess 
the responsiveness of the measure. While a proportion of 
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IPF patients completed the measure at multiple time points, 
FVC and HRQoL did not change sufficiently between meas-
urements (typically 3 months apart) to identify groups of 
patients with varying degrees of change. A final limitation 
is that this primary validation study enrolled patient samples 
obtained in the Netherlands; consequently, validation of this 
instrument in international settings is unknown and must 
be tested.
Further use of the PESaM questionnaire in clinical stud-
ies, accompanied by validity research, is recommended to 
assess the validity in a variety of patient groups with drug 
therapies that differ in terms of administration modes and 
therapeutic effects, as well as the reliability of the meas-
ure. Longitudinal data are needed to support testing of the 
responsiveness and to identify the minimally important 
difference of the measure. Furthermore, the relationship 
between patient experiences and issues such as medication 
adherence and switching (e.g. behavioural response), as well 
as the potential of the PESaM questionnaire to assist shared 
decision making in clinical practice, are areas of interest for 
future research.
5  Conclusions
The PESaM questionnaire is a unique patient-reported out-
come measure evaluating patient experiences and satisfac-
tion with medications. It has been developed in response to 
a request from patient organizations and clinicians, and in 
conjunction with patients, ensuring coverage of domains and 
issues relevant from the patient’s perspective. Results of this 
first validity study are promising, with the generic module 
showing sound structural properties, internal consistency, 
and construct validity. Further research is encouraged to 
examine the reliability and responsiveness in more detail and 
assess the generalizability of the results to support broader 
implementation of the measure.
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